Center-Authored Papers

Filters: Author is Wen, Patrick Y  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR et al..  2011.  Central nervous system cancers.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(4):352-400.
Lin NU, Lee EQ, Aoyama H, Barani IJ, Baumert BG, Brown PD, Camidge RD, Chang SM, Dancey J, Gaspar LE et al..  2013.  Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.. The lancet oncology. 14(10):e396-406. Abstract
Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A, Paddison PJ, Heffron TP, Elmquist WF, Lachowicz JE et al..  2015.  CNS Anticancer Drug Discovery and Development Conference White Paper.. Neuro-oncology. 17 Suppl 6:vi1-26. Abstract
I
Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS et al..  2012.  Initial treatment patterns over time for anaplastic oligodendroglial tumors.. Neuro-oncology. 14(6):761-7. Abstract
L
Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E et al..  2016.  Leptomeningeal metastases: a RANO proposal for response criteria.. Neuro-oncology. Abstract
Chamberlain M, Soffietti R, Raizer J, Rudà R, Brandsma D, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Junck L et al..  2014.  Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials.. Neuro-oncology. Abstract
N
Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J et al..  2017.  The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.. Neuro-oncology. 19(5):625-635. Abstract
Chamberlain MC, Cloughsey T, Reardon DA, Wen PY.  2012.  A novel treatment for glioblastoma: integrin inhibition.. Expert review of neurotherapeutics. 12(4):421-35. Abstract
P
Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY.  2015.  Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.. Cancer. Abstract
Chamberlain MC, Wen PY, Norden AD.  2015.  Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.. Neurology. 85(12):1090.
R
Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ et al..  2014.  Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.. Neuro-oncology. Abstract
Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS et al..  2012.  Response to Weltman and Fleury Malheiros, re Lassman et al.. Neuro-oncology. 14(6):677-678.
U
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen GA, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB et al..  2010.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(11):1963-72. Abstract